Dr. Reddy's Laboratories Ltd
corporate_fare Company Profile
Dr. Reddy's Laboratories Ltd (NYSE:RDY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 32 items for RDY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 8/10, with 15 rated 8 or above. Recent SEC coverage for RDY spans 6-K, 20-F.
Recent high-impact activity:
- Dr. Reddy's Secures Exclusive India Rights to Takeda's Qdenga Dengue Vaccine
- USFDA Flags Two Observations at Dr. Reddy's Mexico API Facility
- Third FDA Form 483 in Two Months Hits Dr. Reddy's
- Dr. Reddy's Secures U.S. FDA Approval for Rituximab Biosimilar; Fresenius Kabi to Lead Commercialization
- Dr. Reddy's Receives Second FDA Form 483 in a Month, This Time for Its Srikakulam Plant
Financial Snapshot
Insider Transactions
RDY files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.